vs
MARCUS CORP（MCS）与Penumbra Inc（PEN）财务数据对比。点击上方公司名可切换其他公司
Penumbra Inc的季度营收约是MARCUS CORP的2.0倍（$385.4M vs $193.5M），Penumbra Inc同比增速更快（22.1% vs 2.8%），Penumbra Inc自由现金流更多（$68.0M vs $26.4M），过去两年MARCUS CORP的营收复合增速更高（18.2% vs 17.6%）
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
Penumbra Inc是2004年由Arani Bose与Adam Elsesser联合创立的美国医疗器械企业，总部位于加利福尼亚州阿拉米达，核心业务为研发、生产中风、动脉瘤等血管疾病介入治疗所用的专业医疗设备，产品已在全球多个国家的临床诊疗场景中投入使用。
MCS vs PEN — 直观对比
营收规模更大
PEN
是对方的2.0倍
$193.5M
营收增速更快
PEN
高出19.4%
2.8%
自由现金流更多
PEN
多$41.7M
$26.4M
两年增速更快
MCS
近两年复合增速
17.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $193.5M | $385.4M |
| 净利润 | — | $47.3M |
| 毛利率 | — | 68.0% |
| 营业利润率 | 0.9% | 15.4% |
| 净利率 | — | 12.3% |
| 营收同比 | 2.8% | 22.1% |
| 净利润同比 | — | 40.6% |
| 每股收益（稀释后） | — | $1.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCSPEN
| Q4 25 | $193.5M | $385.4M | ||
| Q3 25 | $210.2M | $354.7M | ||
| Q2 25 | $206.0M | $339.5M | ||
| Q1 25 | $148.8M | $324.1M | ||
| Q4 24 | $188.3M | $315.5M | ||
| Q3 24 | $232.7M | $301.0M | ||
| Q2 24 | $176.0M | $299.4M | ||
| Q1 24 | $138.5M | $278.7M |
净利润MCSPEN
| Q4 25 | — | $47.3M | ||
| Q3 25 | $16.2M | $45.9M | ||
| Q2 25 | $7.3M | $45.3M | ||
| Q1 25 | $-16.8M | $39.2M | ||
| Q4 24 | $986.0K | $33.7M | ||
| Q3 24 | $23.3M | $29.5M | ||
| Q2 24 | $-20.2M | $-60.2M | ||
| Q1 24 | $-11.9M | $11.0M |
毛利率MCSPEN
| Q4 25 | — | 68.0% | ||
| Q3 25 | — | 67.8% | ||
| Q2 25 | — | 66.0% | ||
| Q1 25 | — | 66.6% | ||
| Q4 24 | — | 66.8% | ||
| Q3 24 | — | 66.5% | ||
| Q2 24 | — | 54.4% | ||
| Q1 24 | — | 65.0% |
营业利润率MCSPEN
| Q4 25 | 0.9% | 15.4% | ||
| Q3 25 | 10.8% | 13.8% | ||
| Q2 25 | 6.3% | 12.0% | ||
| Q1 25 | -13.7% | 12.4% | ||
| Q4 24 | -1.2% | 13.6% | ||
| Q3 24 | 14.1% | 11.7% | ||
| Q2 24 | 1.3% | -27.0% | ||
| Q1 24 | -12.0% | 4.3% |
净利率MCSPEN
| Q4 25 | — | 12.3% | ||
| Q3 25 | 7.7% | 12.9% | ||
| Q2 25 | 3.6% | 13.3% | ||
| Q1 25 | -11.3% | 12.1% | ||
| Q4 24 | 0.5% | 10.7% | ||
| Q3 24 | 10.0% | 9.8% | ||
| Q2 24 | -11.5% | -20.1% | ||
| Q1 24 | -8.6% | 3.9% |
每股收益（稀释后）MCSPEN
| Q4 25 | — | $1.20 | ||
| Q3 25 | — | $1.17 | ||
| Q2 25 | — | $1.15 | ||
| Q1 25 | — | $1.00 | ||
| Q4 24 | — | $0.88 | ||
| Q3 24 | — | $0.75 | ||
| Q2 24 | — | $-1.55 | ||
| Q1 24 | — | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $186.9M |
| 总债务越低越好 | $159.0M | — |
| 股东权益账面价值 | $457.4M | $1.4B |
| 总资产 | $1.0B | $1.8B |
| 负债/权益比越低杠杆越低 | 0.35× | — |
8季度趋势，按日历期对齐
现金及短期投资MCSPEN
| Q4 25 | $23.4M | $186.9M | ||
| Q3 25 | $7.4M | $321.0M | ||
| Q2 25 | $14.9M | $421.8M | ||
| Q1 25 | $11.9M | $376.1M | ||
| Q4 24 | $40.8M | $324.4M | ||
| Q3 24 | $28.4M | $280.5M | ||
| Q2 24 | $32.8M | $288.3M | ||
| Q1 24 | $17.3M | $223.1M |
总债务MCSPEN
| Q4 25 | $159.0M | — | ||
| Q3 25 | $162.0M | — | ||
| Q2 25 | $179.9M | — | ||
| Q1 25 | $198.9M | — | ||
| Q4 24 | $159.1M | — | ||
| Q3 24 | $173.1M | — | ||
| Q2 24 | $175.7M | — | ||
| Q1 24 | $169.8M | — |
股东权益MCSPEN
| Q4 25 | $457.4M | $1.4B | ||
| Q3 25 | $454.3M | $1.4B | ||
| Q2 25 | $448.4M | $1.3B | ||
| Q1 25 | $441.8M | $1.2B | ||
| Q4 24 | $464.9M | $1.2B | ||
| Q3 24 | $462.3M | $1.1B | ||
| Q2 24 | $449.4M | $1.2B | ||
| Q1 24 | $459.3M | $1.2B |
总资产MCSPEN
| Q4 25 | $1.0B | $1.8B | ||
| Q3 25 | $1.0B | $1.7B | ||
| Q2 25 | $1.0B | $1.7B | ||
| Q1 25 | $1.0B | $1.6B | ||
| Q4 24 | $1.0B | $1.5B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $1.1B | $1.5B | ||
| Q1 24 | $1.0B | $1.6B |
负债/权益比MCSPEN
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.8M | $86.5M |
| 自由现金流经营现金流 - 资本支出 | $26.4M | $68.0M |
| 自由现金流率自由现金流/营收 | 13.6% | 17.7% |
| 资本支出强度资本支出/营收 | 11.6% | 4.8% |
| 现金转化率经营现金流/净利润 | — | 1.83× |
| 过去12个月自由现金流最近4个季度 | $989.0K | $174.9M |
8季度趋势，按日历期对齐
经营现金流MCSPEN
| Q4 25 | $48.8M | $86.5M | ||
| Q3 25 | $39.1M | $58.3M | ||
| Q2 25 | $31.6M | $44.9M | ||
| Q1 25 | $-35.3M | $49.0M | ||
| Q4 24 | $52.6M | $51.1M | ||
| Q3 24 | $30.5M | $56.5M | ||
| Q2 24 | $36.0M | $22.6M | ||
| Q1 24 | $-15.1M | $38.3M |
自由现金流MCSPEN
| Q4 25 | $26.4M | $68.0M | ||
| Q3 25 | $18.2M | $42.0M | ||
| Q2 25 | $14.7M | $29.4M | ||
| Q1 25 | $-58.3M | $35.5M | ||
| Q4 24 | $27.1M | $45.7M | ||
| Q3 24 | $12.0M | $51.0M | ||
| Q2 24 | $16.1M | $18.1M | ||
| Q1 24 | $-30.5M | $32.5M |
自由现金流率MCSPEN
| Q4 25 | 13.6% | 17.7% | ||
| Q3 25 | 8.7% | 11.8% | ||
| Q2 25 | 7.1% | 8.7% | ||
| Q1 25 | -39.2% | 11.0% | ||
| Q4 24 | 14.4% | 14.5% | ||
| Q3 24 | 5.2% | 16.9% | ||
| Q2 24 | 9.2% | 6.0% | ||
| Q1 24 | -22.0% | 11.7% |
资本支出强度MCSPEN
| Q4 25 | 11.6% | 4.8% | ||
| Q3 25 | 9.9% | 4.6% | ||
| Q2 25 | 8.2% | 4.6% | ||
| Q1 25 | 15.5% | 4.2% | ||
| Q4 24 | 13.5% | 1.7% | ||
| Q3 24 | 7.9% | 1.8% | ||
| Q2 24 | 11.3% | 1.5% | ||
| Q1 24 | 11.1% | 2.1% |
现金转化率MCSPEN
| Q4 25 | — | 1.83× | ||
| Q3 25 | 2.41× | 1.27× | ||
| Q2 25 | 4.32× | 0.99× | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | 53.31× | 1.52× | ||
| Q3 24 | 1.31× | 1.91× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
PEN
| Thrombectomy | $254.7M | 66% |
| Other | $130.7M | 34% |
